Item 8.01 Other Events
On January 25, 2021, DURECT Corporation issued a press release announcing that
it has dosed the first patient in its AHFIRM randomized, double-blind,
placebo-controlled, multi-center Phase 2b study to evaluate the safety and
efficacy of DUR-928 in severe alcohol-associated hepatitis (AH) patients. A copy
of the press release is attached as Exhibit 99.1 to this Form 8-K and
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release of DURECT Corporation dated January 25, 20 21
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
3
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses